ArticleBiological trace element research2024
Selenium-Methionine-Folic Acid Nanoparticles (SeMetFa NPs) and Its In Vivo Efficacy Against Rheumatoid Arthritis.
Article in Biological trace element research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Trace Elements-Role in Joint Function and Impact on Joint Diseases.International journal of molecular sciences · 2025Review
- Selenium-containing nanoparticles and bone related disorders: from synthesis, bone metabolism to disease therapy.Frontiers in endocrinology · 2025Review
- Selenium Nanoparticles: Biomedical Application Advances and New Stomatology Pathways.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium nanoparticles can be beneficial against rheumatoid arthritis, with limitations in dosage formulation due to their toxicity and low bioavailability. In the present study, we investigated the bioavailability and in vivo efficiency of selenium-methionine-folic acid nanoparticles (SeMetFa NPs) in chronic inflammatory arthritis in rats. The purpose of this study was to develop a therapeutic agent that is of low toxicity and readily available for the maintenance of rheumatoid arthritis. SeMetFa NPs were synthesised by a wet chemical method (precipitation using a reducing agent). The apparent permeability (Papp) of NPs was investigated to be 10 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.